On April 22, 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, reported that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held May 29 – June 2 in Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encouraging efficacy and safety findings, at the 2025 European Society for Medical Oncology Congress (ESMO 2025).
Oral Presentation
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer – (Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique Berton, MD, Institut de Cancérologie de l’Ouest; et al)
Presenter: Professor Yohann Loriot, Gustave Roussy (Paris)
Session Date and Time: May 29, 4:57 PM CDT
Session Title: Gynecological Cancer
Abstract #: 5508
Poster Presentation:
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma – (Charlene Mantia, MD, Glenn J Hanna, MD; Dana Farber, et al)
Presenter: Charlene Mantia, MD, Dana Farber Cancer Institute (Boston)
Session Date and Time: May 30, 4:30 PM CDT
Session Title: Head and Neck Cancer
Abstract #: 6062
Poster Board: 519
The abstracts will be available on the ASCO (Free ASCO Whitepaper) website on May 21, 2026 at 5:00 p.m. ET.
Corbus expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026.
Corbus also anticipates reporting data with CRB-701 in combination with Keytruda in first-line HNSCC patients in Q4 2026 to support potential further registration-enabling trials.
About CRB-701
CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.
(Press release, Corbus Pharmaceuticals, APR 22, 2026, View Source [SID1234664679])